Oncternal Therapeutics Inc.
News
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
Globe Newswire SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the Company ) today announced its decision to discontinue its clinical trials evaluating ONCT-534, its...\n more…
Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com
Zolmax Stock analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT - Get Free Report) in a research report issued on Sunday. The brokerage set a "hold" rating on the...\n more…
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com
Ticker Report Stock analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT - Get Free Report) in a research report issued to clients and investors on Sunday. The firm set a...\n more…
Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com
Ticker Report Analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT - Get Free Report) in a research note issued to investors on Saturday. The firm set a "hold" rating on the...\n more…
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com
Ticker Report StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT - Free Report) in a research report sent to investors on Friday. The firm issued a hold rating on the stock...\n more…
Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com
Ticker Report Stock analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT - Get Free Report) in a note issued to investors on Thursday. The firm set a "hold" rating on the...\n more…